Question 1

Which countries lead Breast Lesions and Carcinomas research?

Accepted Answer

By volume, the United States and China publish the most (1.1k and 932 works in 2022-now).

Question 2

Which institutions lead Breast Lesions and Carcinomas research?

Accepted Answer

By volume in 2022-now, Harvard University publishes the most Breast Lesions and Carcinomas research, followed by All India Institute of Medical Sciences and Mayo Clinic.

Question 3

Who are the leading researchers in Breast Lesions and Carcinomas?

Accepted Answer

The most-cited researchers publishing on Breast Lesions and Carcinomas include Ahmedin Jemal, Freddie Bray and Walter Churchill Willett.

Question 4

Where is Breast Lesions and Carcinomas research done?

Accepted Answer

The largest centres of Breast Lesions and Carcinomas research in 2022-now are Beijing (China), Seoul (South Korea), New York (United States) and Shanghai (China).

Question 5

Where is the best place to study Breast Lesions and Carcinomas?

Accepted Answer

Among universities, judged by research, Humanitas University, Harvard University and Harbin Medical University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

Question 6

Is Breast Lesions and Carcinomas research growing?

Accepted Answer

Output in 2022-2025 was 5% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Breast Lesions and Carcinomas.

Question 7

What are the most cited papers in Breast Lesions and Carcinomas?

Accepted Answer

The most cited paper in Breast Lesions and Carcinomas is "Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer" (Reiki Nishimura, Tomofumi Osako, Yasuyuki Nishiyama et al., 2013), with 13,212 citations. Next come "A Gene-Expression Signature as a Predictor of Survival in Breast Cancer" (6,562) and "A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer" (6,414).